Xos (XOS) 10-K/A 14 May 21 2020 FY Annual report (amended) Financial data

Document And Entity Information

Document And Entity Information - USD ($)	5 Months Ended
	Dec. 31, 2020	Mar. 26, 2021
Document Information Line Items
Entity Registrant Name	NextGen Acquisition Corp
Document Type	10-K/A
Current Fiscal Year End Date	--12-31
Entity Public Float	$ 377,625,000
Amendment Flag	true
Amendment Description	References throughout this Amendment No. 1 to the Annual Report on Form 10-K to “we,” “us,” the “Company” or “our company” are to NextGen Acquisition Corporation unless the context otherwise indicates.This Amendment No. 1 (“Amendment No. 1”) to the Annual Report on Form 10-K/A amends the Annual Report on Form 10-K of NextGen Acquisition Corporation for the fiscal year ended December 31, 2020, as filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2021 (the “Original Filing”).On April 12, 2021, the staff of the Securities and Exchange Commission (the “SEC Staff”) issued a public statement entitled “Staff Statement on Accounting and Reporting Considerations for Warrants issued by Special Purpose Acquisition Companies (“SPACs”)” (the “SEC Staff Statement”). In the SEC Staff Statement, the SEC Staff expressed its view that certain terms and conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC’s balance sheet as opposed to equity. Since issuance on October 9, 2020, our warrants were accounted for as equity within our balance sheet. After discussion and evaluation, including with our independent registered public accounting firm and our audit committee, and taking into consideration the SEC Staff Statement, we have concluded that our warrants should be presented as liabilities with subsequent fair value remeasurement.As a result of the foregoing, on May 12, 2021, our audit committee, in consultation with our management, concluded that our previously issued financial statements as of December 31, 2020 and for the period from July 29, 2020 (inception) through December 31, 2020 (collectively, the “Affected Periods”) should be restated because of a misapplication in the guidance around accounting for our outstanding warrants to purchase Class A ordinary shares (the “Warrants”) and should no longer be relied upon.Historically, the Warrants were reflected as a component of equity as opposed to liabilities on the balance sheets and the statements of operations did not include the subsequent non-cash changes in estimated fair value of the Warrants, based on our application of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815-40, Derivatives and Hedging, Contracts in Entity’s Own Equity (“ASC 815-40”). The views expressed in the SEC Staff Statement were not consistent with our historical interpretation of the specific provisions within its warrant agreement and our application of ASC 815-40 to the warrant agreement. We reassessed our accounting for the Warrants issued on October 9, 2020, in light of the SEC Staff’s published views. Based on this reassessment, we determined that the Warrants should be classified as liabilities measured at fair value upon issuance, with subsequent changes in fair value reported in our statement of operations for each reporting period.The change in accounting for the Warrants did not have any impact on our liquidity, cash flows, revenues or costs of operating our business, in all of the Affected Periods or in any of the periods included in Item 8, “Financial Statements and Supplementary Data” in this filing. The change in accounting for the Warrants does not impact the amounts previously reported for our cash and cash equivalents, investments held in the trust account, or total cash flows from operations for any of these periods.We are filing this Amendment No. 1 to include (i) certain restated items on the previously issued balance sheet dated as of October 9, 2020, the date that the IPO closed, that were previously reported on a Current Report on Form 8-K filed with the SEC on October 15, 2020, and (ii) restated financial statements as of December 31, 2020 and for the period from July 29, 2020 through December 31, 2020 that were previously reported on the Original Filing. The following items have been amended to reflect the restatements:Part I, Item 1A. Risk FactorsPart II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of OperationsPart II, Item 8. Financial Statements and Supplementary DataPart II, Item 9.A. Controls and ProceduresPart IV, Item 15. Exhibits, Financial Statement SchedulesIn addition, the Company’s Principal Executive and Principal Financial Officer has provided new certifications dated as of the date of this filing in connection with this Form 10-K/A (Exhibits 31.1 and 32.1).Except as described above, no other information included in the Original Filing is being amended or updated by this Amendment No. 1 and this Amendment No. 1 does not purport to reflect any information or events subsequent to the Original Filing. This Amendment No. 1 continues to describe the conditions as of the date of the Original Filing and, except as expressly contained herein, we have not updated, modified or supplemented the disclosures contained in the Original Filing. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Filing and with our filings with the SEC subsequent to the Original Filing.
Entity Central Index Key	0001819493
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	true
Entity Ex Transition Period	false
Entity Incorporation, State or Country Code	E9
Document Transition Report	false
Entity File Number	001-39598
Entity Interactive Data Current	Yes
Class A ordinary shares
Document Information Line Items
Entity Common Stock, Shares Outstanding		37,500,000
Class B ordinary shares
Document Information Line Items
Entity Common Stock, Shares Outstanding		9,375,000

Balance Sheet

Balance Sheet	Dec. 31, 2020USD ($)
Current assets:
Cash	$ 821,331
Prepaid expenses	443,165
Total current assets	1,264,496
Investments held in Trust Account	375,007,974
Total Assets	376,272,470
Current liabilities:
Accounts payable	5,497
Accrued expenses	117,238
Total current liabilities	122,735
Derivative warrant liabilities	28,500,590
Deferred underwriting commissions in connection with the initial public offering	13,125,000
Total liabilities	41,748,325
Commitments and Contingencies
Class A ordinary shares subject to possible redemption; 32,952,414 shares at $10.00 per share	329,524,140
Shareholders’ Equity:
Preference shares, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding
Class A ordinary shares, $0.0001 par value; 500,000,000 shares authorized; 4,547,586 shares issued and outstanding (excluding 32,952,414 shares subject to possible redemption)	455
Class B ordinary shares, $0.0001 par value; 50,000,000 shares authorized; 9,375,000 shares issued and outstanding	937
Additional paid-in capital	11,672,764
Accumulated deficit	(6,674,151)
Total shareholders’ equity	5,000,005
Total Liabilities and Shareholders’ Equity	$ 376,272,470

Balance Sheet (Parentheticals)

Balance Sheet (Parentheticals)	5 Months Ended
	Dec. 31, 2020$ / sharesshares
Shares subject to possible redemption	32,952,414
Redemption price per share (in Dollars per share) | $ / shares	$ 10
Preferred stock, par value (in Dollars per share) | $ / shares	$ 0.0001
Preferred stock, shares authorized	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Class A Ordinary Shares
Common stock, par value (in Dollars per share) | $ / shares	$ 0.0001
Common stock, shares authorized	500,000,000
Common stock, shares issued	4,547,586
Common stock, shares outstanding	4,547,586
Class B Ordinary Shares
Common stock, par value (in Dollars per share) | $ / shares	$ 0.0001
Common stock, shares authorized	50,000,000
Common stock, shares issued	9,375,000
Common stock, shares outstanding	9,375,000

Statement of Operations

Statement of Operations	5 Months Ended
	Dec. 31, 2020USD ($)$ / sharesshares
Operating expenses
General and administrative expenses	$ 330,420
General and administrative expenses - related party	30,000
Total operating expenses	(360,420)
Other (expense) income:
Change in fair value of derivative warrant liabilities	(5,458,920)
Financing cost - derivative warrant liabilities	(862,785)
Net gain from cash equivalents held in Trust Account	7,974
Net loss	$ (6,674,151)
Weighted average shares outstanding of Class A ordinary shares subject to possible redemption, basic and diluted (in Shares) | shares	32,831,343
Basic and diluted net income per share, Class A ordinary shares subject to possible redemption (in Dollars per share) | $ / shares
Weighted average shares outstanding of non-redeemable ordinary shares, basic and diluted (in Shares) | shares	11,002,709
Basic and diluted net loss per share, non-redeemable ordinary shares (in Dollars per share) | $ / shares	$ (0.61)

Statement of Changes in Shareho

Statement of Changes in Shareholders’ Equity - 5 months ended Dec. 31, 2020 - USD ($)	Class A Ordinary Shares	Class B Ordinary Shares	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Jul. 28, 2020
Balance (in Shares) at Jul. 28, 2020
Issuance of Class B ordinary shares to Sponsor		$ 1,006	23,994		25,000
Issuance of Class B ordinary shares to Sponsor (in Shares)		10,062,500
Sale of units in initial public offering, less derivative liabilities for public warrants	$ 3,750		359,871,250		359,875,000
Sale of units in initial public offering, less derivative liabilities for public warrants (in Shares)	37,500,000
Offering costs			(20,285,036)		(20,285,036)
Excess cash received over the fair value of the private warrants			1,583,332		1,583,332
Shares subject to possible redemption	$ (3,295)		(329,520,845)		(329,524,140)
Shares subject to possible redemption (in Shares)	(32,952,414)
Forfeiture of Class B shares		$ (69)	69
Forfeiture of Class B shares (in Shares)		(687,500)
Net loss				(6,674,151)	(6,674,151)
Balance at Dec. 31, 2020	$ 455	$ 937	$ 11,672,764	$ (6,674,151)	$ 5,000,005
Balance (in Shares) at Dec. 31, 2020	4,547,586	9,375,000

Statement of Cash Flows

Statement of Cash Flows	5 Months Ended
	Dec. 31, 2020USD ($)
Cash Flows from Operating Activities:
Net loss	$ (6,674,151)
Adjustments to reconcile net loss to net cash used in operating activities:
General and administrative expenses paid by Sponsor in exchange for issuance of Class B ordinary shares	25,000
Net gain from investments held in Trust Account	(7,974)
Change in fair value of derivative warrant liabilities	5,458,920
Financing cost - derivative warrant liabilities	862,785
Changes in operating assets and liabilities:
Prepaid expenses	(443,165)
Accounts payable	5,497
Accrued expenses	47,238
Net cash used in operating activities	(725,850)
Cash Flows from Investing Activities:
Cash deposited in Trust Account	(375,000,000)
Net cash used in investing activities	(375,000,000)
Cash Flows from Financing Activities:
Proceeds from note payable to related party	300,000
Repayment of note payable to related party	(300,000)
Proceeds received from initial public offering, gross	375,000,000
Proceeds received from private placement	9,500,002
Offering costs paid	(7,952,821)
Net cash provided by financing activities	376,547,181
Net increase in cash	821,331
Cash - beginning of the period
Cash - ending of the period	821,331
Supplemental disclosure of noncash investing and financing activities:
Offering costs included in accrued expenses	70,000
Deferred underwriting commissions in connection with the initial public offering	13,125,000
Initial value of Class A ordinary share subject to possible redemption	312,603,060
Change in value of Class A ordinary share subject to possible redemption	$ 16,921,080

Description of Organization, Bu

Description of Organization, Business Operations and Basis of Presentation	5 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Description of Organization, Business Operations and Basis of Presentation	Note 1—Description of Organization, Business Operations and Basis of Presentation NextGen Acquisition Corporation (the “Company”) is a blank check company incorporated as a Cayman Islands exempted company on July 29, 2020. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (“Business Combination”). The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies. As of December 31, 2020, the Company had not commenced any operations. All activity for the period from July 29, 2020 (inception) through December 31, 2020 relates to the Company’s formation and the initial public offering (“Initial Public Offering”) and since the closing of the Initial Public Offering, the search for a prospective initial Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the Initial Public Offering. The Company has selected December 31 as its fiscal year end. The Company’s sponsor is NextGen Sponsor LLC, a Cayman Island exempted company (“Sponsor”). The registration statement for the Company’s Initial Public Offering was declared effective on October 6, 2020. On October 9, 2020, the Company consummated its Initial Public Offering of 35,000,000 units (the “Units” and, with respect to the Class A ordinary shares included in the Units being offered, the “Public Shares”), at $10.00 per Unit, generating gross proceeds of $350.0 million, and incurring offering costs of approximately $19.8 million, inclusive of approximately $12.3 million in deferred underwriting commissions (Note 7). On November 13, 2020, the underwriters partially exercised the over-allotment option and on November 17, 2020, purchased an additional 2,500,000 Units (the “Over-Allotment Units”), generating gross proceeds of $25.0 million, and incurred additional offering costs of approximately $1.4 million in underwriting fees (inclusive of $875,000 in deferred underwriting fees) (the “Over-Allotment”). Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (“Private Placement”) of 6,000,000 warrants (each, a “Private Placement Warrant” and collectively, the “Private Placement Warrants”), at a price of $1.50 per Private Placement Warrant with the Sponsor, generating gross proceeds of $9.0 million (Note 5). Simultaneously with the closing of the Over-Allotment on November 17, 2020, the Company consummated the second closing of the Private Placement, resulting in the purchase of an aggregate of an additional 333,334 Private Placement Warrants by the Sponsor, generating gross proceeds to the Company of $500,000. Upon the closing of the Initial Public Offering, the Over-Allotment and the Private Placement, $375.0 million ($10.00 per Unit) of the net proceeds of the sale of the Units in the Initial Public Offering and the Private Placement were placed in a trust account (“Trust Account”) with Continental Stock Transfer & Trust Company acting as trustee and invested in United States government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain conditions under Rule 2a-7 under the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below. The Company’s management has broad discretion with respect to the specific application of the net proceeds of its Initial Public Offering, the Over-Allotment and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company’s initial Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (as defined below) (excluding the amount of any deferred underwriting commissions and taxes payable on the income earned on the Trust Account) at the time the Company signs a definitive agreement in connection with the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act 1940, as amended, or the Investment Company Act. The Company will provide its holders of Public Shares (the “Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to Public Shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 7). These Public Shares are recognized at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to the amended and restated memorandum and articles of association which will be adopted by the Company upon the consummation of the Initial Public Offering (the “Amended and Restated Memorandum and Articles of Association”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (the “SEC”), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, a shareholder approval of the transactions is required by law, or the Company decides to obtain shareholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks shareholder approval in connection with a Business Combination, the holders of the Founder Shares prior to this Initial Public Offering (the “Initial Shareholders”) agreed to vote their Founder Shares (as defined in Note 6) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination. In addition, the Initial Shareholders agreed to waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of a Business Combination. In addition, the Company has agreed not to enter into a definitive agreement regarding an initial Business Combination without the prior consent of the Sponsor. Notwithstanding the foregoing, the Company’s Amended and Restated Memorandum and Articles of Association provides for a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Class A ordinary shares sold in the Initial Public Offering, without the prior consent of the Company. The Company’s Sponsor, executive officers and directors agreed not to propose an amendment to the Company’s Amended and Restated Memorandum and Articles of Association that would affect the substance or timing of the Company’s obligation to provide for the redemption of its Public Shares in connection with a Business Combination or to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the Public Shareholders with the opportunity to redeem their Class A ordinary shares in conjunction with any such amendment. If the Company is unable to complete a Business Combination within 24 months from the closing of the Initial Public Offering, or October 9, 2022, (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up; (2) as promptly as reasonably possible but not more than 10 business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $100,000 of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidating distributions, if any); and (3) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the board of directors, liquidate and dissolve, subject in each case to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. The Initial Shareholders agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Shareholders should acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters agreed to waive their rights to their deferred underwriting commission (see Note 7) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Company’s Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only $10.00 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or other similar agreement or business combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have vendors, service providers (except the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. Basis of Presentation The accompanying financial statements are presented in U.S. dollars, in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC. As described in Note 2—Restatement of Previously Issued Financial Statements, the Company’s financial statements as of December 31, 2020, and for the period from July 29, 2020 (inception) through December 31, 2020 (collectively, the “Affected Periods”), are restated in the Annual Report on Form 10-K/A (Amendment No. 1) (the “Annual Report”) to correct the misapplication of accounting guidance related to the Company’s warrants in the Company’s previously issued audited and unaudited condensed financial statements for such periods. The restated financial statements are indicated as “Restated” in the audited and unaudited condensed financial statements and accompanying notes, as applicable. See Note 2—Restatement of Previously Issued Financial Statements for further discussion. Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Risk and Uncertainties On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus (the “COVID-19 outbreak”). In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve. The impact of the COVID-19 outbreak on the Company’s results of operations, financial position and cash flows will depend on future developments, including the duration and spread of the outbreak and related advisories and restrictions. These developments and the impact of the COVID-19 outbreak on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s results of operations, financial position and cash flows may be materially adversely affected. Additionally, the Company’s ability to complete an Initial Business Combination may be materially adversely affected due to significant governmental measures being implemented to contain the COVID-19 outbreak or treat its impact, including travel restrictions, the shutdown of businesses and quarantines, among others, which may limit the Company’s ability to have meetings with potential investors or affect the ability of a potential target company’s personnel, vendors and service providers to negotiate and consummate an Initial Business Combination in a timely manner. The Company’s ability to consummate an Initial Business Combination may also be dependent on the ability to raise additional equity and debt financing, which may be impacted by the COVID-19 outbreak and the resulting market downturn. Liquidity and Capital Resources As of December 31, 2020, the Company had approximately $821,000 in its operating bank account and working capital of approximately $1.2 million. To date, the Company’s liquidity needs were satisfied through a payment of $25,000 from the Sponsor to cover certain expenses on behalf of the Company in exchange for the issuance of the Founder Shares (as defined below), the loan under the Note from the Sponsor of $300,000 (see Note 6) to the Company and the net proceeds from the consummation of the Private Placement not held in the Trust Account. The Company fully repaid the Note on October 8, 2020. In addition, in order to finance transaction costs in connection with a Business Combination, the Company’s officers, directors and Initial Shareholders may, but are not obligated to, provide the Company Working Capital Loans (see Note 6). Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity to meet its needs through the earlier of the consummation of a Business Combination or one year from this filing. Over this time period, the Company will be using these funds held outside of the Trust Account for paying existing accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination.

Restatement of Previously Issue

Restatement of Previously Issued Financial Statements	5 Months Ended
	Dec. 31, 2020
Condensed Financial Information Disclosure [Abstract]
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS	Note 2 — RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS On May 12, 2021, the audit committee of the Company, in consultation with management, concluded that, because of a misapplication of the accounting guidance related to its Public Warrants and Private Placement Warrants to purchase Class A ordinary shares that the Company issued in October 2020 (collectively the “Warrants”), the Company’s previously issued financial statements for the Affected Periods should no longer be relied upon. As such, the Company is restating its financial statements for the Affected Periods included in this Annual Report. On April 12, 2021, the staff of the Securities and Exchange Commission (the “SEC Staff”) issued a public statement entitled “Staff Statement on Accounting and Reporting Considerations for Warrants issued by Special Purpose Acquisition Companies (“SPACs”)” (the “SEC Staff Statement”). In the SEC Staff Statement, the SEC Staff expressed its view that certain terms and conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC’s balance sheet as opposed to equity. Since issuance on October 9, 2020, the Company’s Warrants were accounted for as equity within the Company’s previously reported balance sheets. After discussion and evaluation, including with the Company’s independent registered public accounting firm and the Company’s audit committee, management concluded that the Warrants should be presented as liabilities with subsequent fair value remeasurement. Historically, the Warrants were reflected as a component of equity as opposed to liabilities on the balance sheets and the statements of operations did not include the subsequent non-cash changes in estimated fair value of the Warrants, based on our application of FASB ASC Topic 815-40, Derivatives and Hedging, Contracts in Entity’s Own Equity (“ASC 815-40”). The views expressed in the SEC Staff Statement were not consistent with the Company’s historical interpretation of the specific provisions within its warrant agreement and the Company’s application of ASC 815-40 to the warrant agreement. The Company reassessed its accounting for the Warrants, in light of the SEC Staff’s published views. Based on this reassessment, management determined that the Warrants should be classified as liabilities measured at fair value upon issuance, with subsequent changes in fair value reported in the Company’s statement of operations each reporting period. Therefore, the Company, in consultation with its audit committee, concluded that its previously issued financial statements as of December 31, 2020 and for the period from July 29, 2020 (inception) through December 31, 2020, should be restated because of a misapplication in the guidance around accounting for the Warrants and should no longer be relied upon. Impact of the Restatement The impact of the restatement on the balance sheets, statements of operations and statements of cash flows for the Affected Periods is presented below. The restatement had no impact on net cash flows from operating, investing or financing activities. As of December 31, 2020 As Previously Restatement As Restated Balance Sheet Total assets $ 376,272,470 $ - $ 376,272,470 Liabilities and Shareholders’ Equity Total current liabilities $ 122,735 $ - $ 122,735 Deferred underwriting commissions 13,125,000 - 13,125,000 Derivative warrant liabilities - 28,500,590 28,500,590 Total liabilities 13,247,735 28,500,590 41,748,325 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption 358,024,730 (28,500,590 ) 329,524,140 Shareholders’ equity Preference shares - $0.0001 par value - - - Class A ordinary shares - $0.0001 par value 170 285 455 Class B ordinary shares - $0.0001 par value 937 937 Additional paid-in-capital 5,351,344 6,321,420 11,672,764 Accumulated deficit (352,446 ) (6,321,705 ) (6,674,151 ) Total shareholders’ equity 5,000,005 - 5,000,005 Total liabilities and shareholders’ equity $ 376,272,470 - $ 376,272,470 Period From July 29, 2020 (Inception) Through As Previously Restatement As Restated Statement of Operations and Comprehensive Loss Loss from operations $ (360,420 ) $ - $ (360,420 ) Other (expense) income: Change in fair value of derivative warrant liabilities - (5,458,920 ) (5,458,920 ) Financing cost - derivative warrant liabilities (862,785 ) (862,785 ) Net gain from cash equivalents held in Trust Account 7,974 - 7,974 Total other (expense) income 7,974 (6,321,705 ) (6,313,731 ) Net loss $ (352,446 ) $ (6,321,705 ) $ (6,674,151 ) Weighted average shares outstanding of Class A ordinary shares subject to possible redemption, basic and diluted 35,001,205 (2,169,862 ) 32,831,343 Basic and diluted net income per share, Class A ordinary shares subject to possible redemption $ - - $ - Weighted average shares outstanding of non-redeemable ordinary shares, basic and diluted 9,819,148 1,183,561 11,002,709 Basic and diluted net loss per share, non-redeemable ordinary shares $ (0.04 ) $ (0.57 ) $ (0.61 ) Period From July 29, 2020 (Inception) Through As Previously Restatement Adjustment As Restated Statement of Cash Flows Net loss $ (352,446 ) $ (6,321,705 ) $ (6,674,151 ) Adjustment to reconcile net loss to net cash used in operating activities (373,404 ) 5,458,920 5,085,516 Net cash used in operating activities (725,850 ) - (725,850 ) Net cash used in investing activities (375,000,000 ) - (375,000,000 ) Net cash provided by financing activities 376,547,181 - 376,547,181 Net change in cash $ 821,331 $ - $ 821,331 In addition, the impact to the balance sheet dated October 9, 2020, filed on Form 8-K on October 15, 2020 related to the impact of accounting for the Warrants as liabilities at fair value resulted in a $21.6 million increase to the derivative warrant liabilities line item as of October 9, 2020 and offsetting decrease to the Class A ordinary shares subject to possible redemption mezzanine equity line item. There is no change to total shareholders’ equity at the reported balance sheet date. As of October 9, 2020 As Previously Restatement As Restated Balance Sheet Total assets $ 351,797,538 $ - $ 351,797,538 Liabilities and shareholders’ equity Total current liabilities $ 327,799 $ - $ 327,799 Deferred underwriting commissions 12,250,000 - 12,250,000 Derivative warrant liabilities - 21,616,670 21,616,670 Total liabilities 12,577,799 21,616,670 34,194,469 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption 334,219,730 (21,616,670 ) 312,603,060 Shareholders’ equity Preference shares - $0.0001 par value - - - Class A ordinary shares - $0.0001 par value 158 216 374 Class B ordinary shares - $0.0001 par value 1,006 - 1,006 Additional paid-in-capital 5,038,954 806,726 5,845,680 Accumulated deficit (40,109 ) (806,942 ) (847,051 ) Total shareholders’ equity 5,000,009 - 5,000,009 Total liabilities and shareholders’ equity $ 351,797,538 - $ 351,797,538

Summary of Significant Accounti

Summary of Significant Accounting Policies	5 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3—Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of December 31, 2020. Investments Held in Trust Account Upon the closing of the Initial Public Offering and the Private Placement, $375.0 million of the net proceeds of the sale of the Units in the Initial Public Offering and the Private Placement were placed in the Trust Account and invested in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations. All of the Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. The estimated fair values of investments held in Trust Account are determined using available market information. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000, and cash equivalents held in Trust Account. On December 31, 2020, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. Fair Value Measurement Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. Fair Value of Financial Instruments As of December 31, 2020, the carrying values of cash, accrued expenses and accrued expenses – related party approximate their fair values due to the short-term nature of the instruments. As of December 31, 2020, the Company’s portfolio of investments held in the Trust Account is comprised entirely of investments in money market funds that invest in U.S. government securities. Offering Costs Associated with the Initial Public Offering Offering costs consisted of legal, accounting, underwriting fees and other costs incurred that were directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with warrant liabilities are expensed as incurred, presented as non-operating expenses in the statement of operations. Offering costs associated with the Public Shares were charged to shareholders’ equity upon the completion of the Initial Public Offering. Of the total offering costs of the Initial Public Offering, approximately $0.9 million is included in financing cost - derivative warrant liabilities in the statement of operations and $20.3 million is included in shareholders’ equity. Class A Ordinary Shares Subject to Possible Redemption The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in FASB ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, on December 31, 2020, 32,952,414 Class A ordinary shares subject to possible redemption are presented as temporary equity, outside of the shareholders’ equity section of the Company’s balance sheet. Derivative Warrant liabilities The Company does not use derivative instruments to hedge its exposures to cash flow, market, or foreign currency risks. Management evaluates all of the Company’s financial instruments, including issued warrants to purchase its Class A ordinary shares, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-15. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. The Company issued 12,500,000 warrants to purchase Class A ordinary shares to investors in the Company’s Initial Public Offering and simultaneously issued 6,333,334 Private Placement Warrants. All of the Company’s outstanding warrants are recognized as derivative liabilities in accordance with ASC 815-40. Accordingly, we recognize the warrant instruments as liabilities at fair value and adjust the instruments to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in our statement of operations. The estimated fair value of the warrants issued in connection with the Initial Public Offering and Private Placement Warrants initially were and subsequently have been measured using a Monte Carlo simulation model when a listed price in an active market is not available for such warrants. Beginning in December 2020, the fair value of warrants issued in connection with the Initial Public Offering have subsequently been measured based on the listed market price of such warrants. Derivative warrant liabilities are classified as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. Income Taxes The Company follows the asset and liability method of accounting for income taxes under FASB ASC Topic 740, “ Income Taxes FASB ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of December 31, 2020. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts were accrued for interest and penalties for the period from July 29, 2020 (inception) through December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company may be subject to potential examination by U.S. federal, U.S. state or foreign taxing authorities in the area of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, U.S. state and foreign tax laws. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, deferred tax assets and income taxes are not reflected in the Company’s financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. Net Loss Per Ordinary Share The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net loss per share is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period excluding ordinary shares subject to forfeiture. An aggregate of 32,952,414 Class A ordinary shares subject to possible redemption on December 31, 2020 has been excluded from the calculation of basic loss per ordinary share, since such shares, if redeemed, only participate in their pro rata share of the trust earnings. The Company has not considered the effect of the warrants sold in the Initial Public Offering (including the consummation of the Over-Allotment Units) and Private Placement to purchase an aggregate of 18,833,334 shares of the Company’s ordinary shares in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events. The Company’s net loss is adjusted for the portion of income (loss) that is attributable to Class A ordinary shares subject to redemption, as these shares only participate in the earnings of the Trust Account and not the income or losses of the Company. Accordingly, basic and diluted loss per ordinary share is calculated as follows: For the Class A ordinary shares subject to possible redemption Numerator: Net gain from investments held in Trust Account $ 7,007 Net income attributable to Class A ordinary shares subject to possible redemption $ 7,007 Denominator: Weighted average shares outstanding of Class A ordinary shares subject to possible redemption, basic and diluted 32,831,343 Basic and diluted net income per share, Class A ordinary shares subject to possible redemption $ 0.00 Non-redeemable ordinary shares Numerator: Net loss $ (6,674,151 ) Less: Net income attributable to Class A ordinary shares subject to possible redemption 7,007 Net loss attributable to non-redeemable ordinary shares $ (6,681,158 ) Denominator: Weighted average shares outstanding of non-redeemable ordinary shares, basic and diluted 11,002,709 Basic and diluted net loss per share, non-redeemable ordinary shares $ (0.61 ) Recent Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the Company’s financial statements.

Initial Public Offering

Initial Public Offering	5 Months Ended
	Dec. 31, 2020
Initial Public Offering [Abstract]
Initial Public Offering	Note 4—Initial Public Offering On October 9, 2020, the Company consummated its Initial Public Offering of 35,000,000 Units, at $10.00 per Unit, generating gross proceeds of $350.0 million, and incurring offering costs of approximately $19.8 million, inclusive of approximately $12.3 million in deferred underwriting commissions. On November 13, 2020, the underwriters partially exercised the over-allotment option and on November 17, 2020, purchased an additional 2,500,000 Over-Allotment Units, generating gross proceeds of $25.0 million, and incurred additional offering costs of approximately $1.4 million in underwriting fees (inclusive of $875,000 in deferred underwriting fees). Each Unit consists of one Class A ordinary share and one-third of one redeemable warrant (“Public Warrant”). Each whole Public Warrant will entitle the holder to purchase one Class A ordinary share at an exercise price of $11.50 per share, subject to adjustment (see Note 8).

Private Placement

Private Placement	5 Months Ended
	Dec. 31, 2020
Private Placement [Abstract]
Private Placement	Note 5—Private Placement Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement of 6,000,000 Private Placement Warrants, at a price of $1.50 per Private Placement Warrant with the Sponsor, generating gross proceeds of $9.0 million. Simultaneously with the closing of the Over-allotment on November 17, 2020, the Company consummated the second closing of the Private Placement, resulting in the purchase of an aggregate of an additional 333,334 Private Placement Warrants by the Sponsor, generating gross proceeds to the Company of $500,000. Each whole Private Placement Warrant is exercisable for one whole share of Class A ordinary shares at a price of $11.50 per share. A portion of the proceeds from the sale of the Private Placement Warrants to the Sponsor was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants will be non-redeemable for cash and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees. The Sponsor and the Company’s officers and directors agreed, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Warrants until 30 days after the completion of the initial Business Combination.

Related Party Transactions

Related Party Transactions	5 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Note 6—Related Party Transactions Founder Shares On July 31, 2020, the Sponsor paid an aggregate of $25,000 to cover for certain expenses on behalf of the Company in exchange for issuance of 10,062,500 Class B ordinary shares (the “Founder Shares”). The holders of the Founder Shares agreed to forfeit up to an aggregate of 1,312,500 Founder Shares, on a pro rata basis, to the extent that the option to purchase additional units is not exercised in full by the underwriters, so that the Founder Shares will represent 20% of the Company’s issued and outstanding shares after the Initial Public Offering. On November 17, 2020, the underwriters partially exercised the over-allotment option to purchase as additional 2,500,000 Units and forfeited the remaining option; thus, an aggregate of 687,500 shares of Class B ordinary shares were forfeited accordingly. The Initial Shareholders agreed not to transfer, assign or sell any of their Founder Shares until the earlier to occur of (A) one year after the completion of the initial Business Combination; and (B) subsequent to the initial Business Combination (x) if the last reported sale price of Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property. Related Party Loans On July 31, 2020, the Sponsor agreed to loan the Company up to $300,000 to be used for the payment of costs related to the Initial Public Offering pursuant to a promissory note (the “Note”). The Note is non-interest bearing, unsecured and due upon the closing of the Initial Public Offering. The Company borrowed $300,000 under the Note and fully repaid the Note on October 8, 2020. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor, members of the Company’s founding team or any of their affiliates may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company will repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post Business Combination entity at a price of $1.50 per warrant. The warrants would be identical to the Private Placement Warrants. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. As of December 31, 2020, the Company had no borrowings under the Working Capital Loans. Administrative Services Agreement The Company executed an Administrative Services Agreement with an affiliate of the Sponsor, pursuant to which the Company will pay a total of $10,000 per month for office space, administrative, financial and support services to such affiliate. Payments under the agreement cease upon completion of the initial Business Combination or liquidation of the Company.

Commitments and Contingencies

Commitments and Contingencies	5 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7—Commitments and Contingencies Registration and Shareholder Rights The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants or warrants issued upon conversion of the Working Capital Loans and upon conversion of the Founder Shares) are entitled to registration rights pursuant to a registration and shareholder rights agreement. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement The Company granted the underwriters a 45-day option from the date of the Initial Public Offering to purchase up to 5,250,000 additional Units at the Initial Public Offering price less the underwriting discounts and commissions. On November 13, 2020, the underwriters partially exercised the over-allotment option and on November 17, 2020, purchased an additional 2,500,000 Over-Allotment Units. The underwriters were entitled to an underwriting discount of $0.20 per unit, or $7.00 million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, $0.35 per unit, or $12.25 million in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. In connection with the consummation of the Over-Allotment on November 17, 2020, the underwriters were entitled to an additional fee of $500,000 paid upon closing, and $875,000 in deferred underwriting commissions. Deferred Legal Fees The Company’s legal counsel agreed to defer their fees in excess of $250,000 until the consummation of the Company’s initial Business Combination. In the event, either (x) the initial Business Combination is not consummated within two years of the Initial Public Offering and the proceeds of the Initial Public Offering are returned to investors, or (y) the legal counsel declined to represent the Company in the initial Business Combination due to a conflict, the legal counsel will write off such deferred amounts. The deferred amount is an unrecognized contingent liability, as closing of a potential business combination was not considered probable as of December 31, 2020.

Warrants

Warrants	5 Months Ended
	Dec. 31, 2020
Disclosure Of Warrants [Abstract]
Warrants	Note 8 - The Company issued 12,500,000 warrants to purchase Class A ordinary shares to investors in the Company’s Initial Public Offering and simultaneously issued 6,333,334 Private Placement Warrants. Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants will be issued upon separation of the Units and only whole Public Warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months from the closing of the Initial Public Offering; provided in each case that the Company has an effective registration statement under the Securities Act covering the issuance of the Class A ordinary shares issuable upon exercise of the warrants and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder (or the Company permits holders to exercise their warrants on a cashless basis under the circumstances specified in the warrant agreement). The Company has agreed that as soon as practicable, but in no event later than 15 business days after the closing of the initial Business Combination, the Company will use its commercially reasonable efforts to file with the SEC a registration statement covering the issuance of the Class A ordinary shares issuable upon exercise of the warrants, and the Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of the initial Business Combination and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed; provided that if the Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, requires holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, it will not be required to file or maintain in effect a registration statement. The warrants have an exercise price of $11.50 per share, subject to adjustments, and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described under “Redemption of warrants for cash when the price per Class A ordinary share equals or exceeds $18.00” and “Redemption of warrants for Class A ordinary shares when the price per Class A ordinary share equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described under the caption “Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants and the Class A ordinary shares issuable upon exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be non-redeemable so long as they are held by the initial purchasers or such purchasers’ permitted transferees. If the Private Placement Warrants are held by someone other than the Initial Shareholders or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. Redemption of warrants for cash when the price per Class A ordinary share equals or exceeds $18.00: Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants): ● in whole and not in part; ● at a price of $0.01 per warrant; ● upon not less than 30 days’ prior written notice of redemption to each warrant holder; and ● if, and only if, the last reported sale price of Class A ordinary shares for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders (the “Reference Value”) equals or exceeds $18.00 per share (as adjusted for share sub-divisions, share dividends, rights issuances, consolidations, reorganizations, recapitalizations and the like). The Company will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the Class A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating to those Class A ordinary shares is available throughout the 30-day redemption period. If and when the warrants become redeemable by the Company, it may exercise its redemption right even if the Company is unable to register or qualify the underlying securities for sale under all applicable state securities laws. Redemption of warrants for Class A ordinary shares when the price per Class A ordinary share equals or exceeds $10.00: Once the warrants become exercisable, the Company may redeem the outstanding warrants (including both Public Warrants and Private Placement Warrants): ● in whole and not in part; ● at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the “fair market value” of Class A ordinary shares; ● if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted for share splits, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like); and ● if the Reference Value is less than $18.00 per share (as adjusted), the Private Placement Warrants must also concurrently be called for redemption on the same terms as the outstanding Public Warrants, as described above. The “fair market value” of Class A ordinary shares shall mean the average reported last sale price of Class A ordinary shares for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. In no event will the Company be required to net cash settle any warrant. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.

Shareholder_s Equity

Shareholder’s Equity	5 Months Ended
	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Shareholders’ Equity	Note 9—Shareholders’ Equity Class A Ordinary Shares Class B Ordinary Shares Holders of the Class A ordinary shares and holders of the Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the shareholders, except as required by law. Each ordinary share will have one vote on all such matters. The Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the initial Business Combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like, and subject to further adjustment as provided herein. In the case that additional Class A ordinary shares, or equity-linked securities, are issued or deemed issued in excess of the amounts issued in the Initial Public Offering and related to the closing of the initial Business Combination, the ratio at which the Class B ordinary shares will convert into Class A ordinary shares will be adjusted (unless the holders of a majority of the issued and outstanding Class B ordinary shares agree to waive such anti-dilution adjustment with respect to any such issuance or deemed issuance) so that the number of Class A ordinary shares issuable upon conversion of all Class B ordinary shares will equal, in the aggregate, on an as-converted basis, 20% of the sum of all ordinary shares issued and outstanding upon the completion of the Initial Public Offering plus all Class A ordinary shares and equity-linked securities issued or deemed issued in connection with the initial Business Combination, excluding any shares or equity-linked securities issued, or to be issued, to any seller in the initial Business Combination. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than one to one. Preference Shares

Fair Value Measurements

Fair Value Measurements	5 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 10—Fair Value Measurements The following table presents information about the Company’s financial liabilities that are measured at fair value on a recurring basis as of December 31, 2020 by level within the fair value hierarchy: Fair Value Measured as of December 31, 2020 Level 1 Level 2 Level 3 Total Liabilities: Derivative warrant liabilities Public Warrants (Restated) $ 18,683,920 $ - $ - $ 18,683,920 Derivative warrant liabilities Private Warrants (Restated) $ - $ - $ 9,816,670 $ 9,816,670 Total fair value $ 18,683,920 $ - $ 9,816,670 $ 28,500,590 Transfers to/from Levels 1, 2, and 3 are recognized at the end of the reporting period. The estimated fair value of the Public Warrants transferred from a Level 3 measurement to a Level 1 fair value measurement in December 2020, when the Public Warrants were separately listed and traded in an active market. The estimated fair value of the warrants issued in connection with the Initial Public Offering and Private Placement Warrants have initially and subsequently been measured using a Monte Carlo simulation model when a listed price in an active market is not available for such warrants. Beginning in December 2020, the fair value of warrants issued in connection with the Initial Public Offering have subsequently been measured based on the listed market price of such warrants. For the period from July 29, 2020 (inception) through December 31, 2020, the Company recognized an unrealized loss resulting from an increase in the fair value of liabilities of approximately $5.5 million presented as change in fair value of derivative warrant liabilities on the accompanying statement of operations. The estimated fair value of the Private Placement Warrants, and the Public Warrants prior to being separately listed and traded, is determined using Level 3 inputs. Inherent in a Monte Carlo simulation are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its ordinary shares based on implied volatility from the Company’s traded warrants and from historical volatility of select peer company’s ordinary shares that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero. The following table provides quantitative information regarding Level 3 fair value measurements inputs at their measurement dates: As of October 09, As of December 31, Exercise price 11.50 11.50 Stock Price 9.60 10.07 Option term (in years) 6.67 6.44 Volatility 19.8 % 21.0 % Risk-free interest rate 0.52 % 0.57 % This reconciles the change in the fair value of the derivative warrant liabilities using Level 3 inputs for the period from July 29, 2020 (inception) through December 31, 2020: Level 3 - Derivatrive warrant liabilities at July 29, 2020 (inception) $ - Level 3 - Derivatrive warrant liabilities at September 30, 2020 - Issuance of Public and Private Warrants 23,041,670 Transfer to Level 1 measurement - Public Warrants (18,683,920 ) Change in fair value of derivative warrant liabilities 5,458,920 Level 3 - Derivative warrant liabilities at December 31, 2020 $ 9,816,670

Subsequent Events

Subsequent Events	5 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Note 11—Subsequent Events On February 21, 2021, the Company entered into an Agreement and Plan of Merger (the “ Merger Agreement Merger Sub Xos Business Combination (i) at the closing of the transactions contemplated by the Merger Agreement (the “ Closing DGCL Merger (ii) as a result of the Merger, among other things, all outstanding shares of common stock of Xos (after giving effect to the Company Recapitalization (as defined in the Merger Agreement)) will be cancelled in exchange for the right to receive, in the aggregate, a number of shares of the Company’s Common Stock (as defined below) equal to the quotient obtained by dividing (x) $1,276,261,160.00 by (y) $10.00; and (iii) upon the effective time of the Domestication (as defined below), the Company will immediately be renamed “Xos, Inc.” or such other name as agreed to by NextGen and Xos prior to Closing. On February 21, 2021, concurrently with the execution of the Merger Agreement, the Company entered into subscription agreements (the “Subscription Agreements”) with certain investors (collectively, the “ PIPE Investors PIPE Investment On March 29, 2021, the Company issued a promissory note to Sponsor (the “Promissory Note”), pursuant to which the Company may borrow up to an aggregate principal amount of $1,000,000. The Promissory Note is non-interest bearing and payable on the earlier of (i) October 9, 2022 and (ii) the completion of the Business Combination. To date, there was $0 outstanding under the Promissory Note. The Company evaluated events that have occurred after the balance sheet date through the date on which the financial statements were issued. Based upon this review, the Company did not identify any other subsequent events that would have required adjustment or disclosure in the financial statements.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	5 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of December 31, 2020.
Investments Held in Trust Account	Investments Held in Trust Account Upon the closing of the Initial Public Offering and the Private Placement, $375.0 million of the net proceeds of the sale of the Units in the Initial Public Offering and the Private Placement were placed in the Trust Account and invested in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations. All of the Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. The estimated fair values of investments held in Trust Account are determined using available market information.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000, and cash equivalents held in Trust Account. On December 31, 2020, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.
Fair Value Measurement	Fair Value Measurement Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
Fair Value of Financial Instruments	Fair Value of Financial Instruments As of December 31, 2020, the carrying values of cash, accrued expenses and accrued expenses – related party approximate their fair values due to the short-term nature of the instruments. As of December 31, 2020, the Company’s portfolio of investments held in the Trust Account is comprised entirely of investments in money market funds that invest in U.S. government securities.
Offering Costs Associated with the Initial Public Offering	Offering Costs Associated with the Initial Public Offering Offering costs consisted of legal, accounting, underwriting fees and other costs incurred that were directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with warrant liabilities are expensed as incurred, presented as non-operating expenses in the statement of operations. Offering costs associated with the Public Shares were charged to shareholders’ equity upon the completion of the Initial Public Offering. Of the total offering costs of the Initial Public Offering, approximately $0.9 million is included in financing cost - derivative warrant liabilities in the statement of operations and $20.3 million is included in shareholders’ equity.
Class A Ordinary Shares Subject to Possible Redemption	Class A Ordinary Shares Subject to Possible Redemption The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in FASB ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, on December 31, 2020, 32,952,414 Class A ordinary shares subject to possible redemption are presented as temporary equity, outside of the shareholders’ equity section of the Company’s balance sheet.
Derivative Warrant liabilities	Derivative Warrant liabilities The Company does not use derivative instruments to hedge its exposures to cash flow, market, or foreign currency risks. Management evaluates all of the Company’s financial instruments, including issued warrants to purchase its Class A ordinary shares, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-15. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. The Company issued 12,500,000 warrants to purchase Class A ordinary shares to investors in the Company’s Initial Public Offering and simultaneously issued 6,333,334 Private Placement Warrants. All of the Company’s outstanding warrants are recognized as derivative liabilities in accordance with ASC 815-40. Accordingly, we recognize the warrant instruments as liabilities at fair value and adjust the instruments to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in our statement of operations. The estimated fair value of the warrants issued in connection with the Initial Public Offering and Private Placement Warrants initially were and subsequently have been measured using a Monte Carlo simulation model when a listed price in an active market is not available for such warrants. Beginning in December 2020, the fair value of warrants issued in connection with the Initial Public Offering have subsequently been measured based on the listed market price of such warrants. Derivative warrant liabilities are classified as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.
Income Taxes	Income Taxes The Company follows the asset and liability method of accounting for income taxes under FASB ASC Topic 740, “ Income Taxes FASB ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of December 31, 2020. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts were accrued for interest and penalties for the period from July 29, 2020 (inception) through December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company may be subject to potential examination by U.S. federal, U.S. state or foreign taxing authorities in the area of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, U.S. state and foreign tax laws. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, deferred tax assets and income taxes are not reflected in the Company’s financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
Net Loss Per Ordinary Share	Net Loss Per Ordinary Share The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net loss per share is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period excluding ordinary shares subject to forfeiture. An aggregate of 32,952,414 Class A ordinary shares subject to possible redemption on December 31, 2020 has been excluded from the calculation of basic loss per ordinary share, since such shares, if redeemed, only participate in their pro rata share of the trust earnings. The Company has not considered the effect of the warrants sold in the Initial Public Offering (including the consummation of the Over-Allotment Units) and Private Placement to purchase an aggregate of 18,833,334 shares of the Company’s ordinary shares in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events. The Company’s net loss is adjusted for the portion of income (loss) that is attributable to Class A ordinary shares subject to redemption, as these shares only participate in the earnings of the Trust Account and not the income or losses of the Company. Accordingly, basic and diluted loss per ordinary share is calculated as follows: For the Class A ordinary shares subject to possible redemption Numerator: Net gain from investments held in Trust Account $ 7,007 Net income attributable to Class A ordinary shares subject to possible redemption $ 7,007 Denominator: Weighted average shares outstanding of Class A ordinary shares subject to possible redemption, basic and diluted 32,831,343 Basic and diluted net income per share, Class A ordinary shares subject to possible redemption $ 0.00 Non-redeemable ordinary shares Numerator: Net loss $ (6,674,151 ) Less: Net income attributable to Class A ordinary shares subject to possible redemption 7,007 Net loss attributable to non-redeemable ordinary shares $ (6,681,158 ) Denominator: Weighted average shares outstanding of non-redeemable ordinary shares, basic and diluted 11,002,709 Basic and diluted net loss per share, non-redeemable ordinary shares $ (0.61 )
Recent Accounting Standards	Recent Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the Company’s financial statements.

Restatement of Previously Iss_2

Restatement of Previously Issued Financial Statements (Tables)	5 Months Ended
	Dec. 31, 2020
Condensed Financial Information Disclosure [Abstract]
Schedule of the restatement on each financial statement	As of December 31, 2020 As Previously Restatement As Restated Balance Sheet Total assets $ 376,272,470 $ - $ 376,272,470 Liabilities and Shareholders’ Equity Total current liabilities $ 122,735 $ - $ 122,735 Deferred underwriting commissions 13,125,000 - 13,125,000 Derivative warrant liabilities - 28,500,590 28,500,590 Total liabilities 13,247,735 28,500,590 41,748,325 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption 358,024,730 (28,500,590 ) 329,524,140 Shareholders’ equity Preference shares - $0.0001 par value - - - Class A ordinary shares - $0.0001 par value 170 285 455 Class B ordinary shares - $0.0001 par value 937 937 Additional paid-in-capital 5,351,344 6,321,420 11,672,764 Accumulated deficit (352,446 ) (6,321,705 ) (6,674,151 ) Total shareholders’ equity 5,000,005 - 5,000,005 Total liabilities and shareholders’ equity $ 376,272,470 - $ 376,272,470 Period From July 29, 2020 (Inception) Through As Previously Restatement As Restated Statement of Operations and Comprehensive Loss Loss from operations $ (360,420 ) $ - $ (360,420 ) Other (expense) income: Change in fair value of derivative warrant liabilities - (5,458,920 ) (5,458,920 ) Financing cost - derivative warrant liabilities (862,785 ) (862,785 ) Net gain from cash equivalents held in Trust Account 7,974 - 7,974 Total other (expense) income 7,974 (6,321,705 ) (6,313,731 ) Net loss $ (352,446 ) $ (6,321,705 ) $ (6,674,151 ) Weighted average shares outstanding of Class A ordinary shares subject to possible redemption, basic and diluted 35,001,205 (2,169,862 ) 32,831,343 Basic and diluted net income per share, Class A ordinary shares subject to possible redemption $ - - $ - Weighted average shares outstanding of non-redeemable ordinary shares, basic and diluted 9,819,148 1,183,561 11,002,709 Basic and diluted net loss per share, non-redeemable ordinary shares $ (0.04 ) $ (0.57 ) $ (0.61 ) Period From July 29, 2020 (Inception) Through As Previously Restatement Adjustment As Restated Statement of Cash Flows Net loss $ (352,446 ) $ (6,321,705 ) $ (6,674,151 ) Adjustment to reconcile net loss to net cash used in operating activities (373,404 ) 5,458,920 5,085,516 Net cash used in operating activities (725,850 ) - (725,850 ) Net cash used in investing activities (375,000,000 ) - (375,000,000 ) Net cash provided by financing activities 376,547,181 - 376,547,181 Net change in cash $ 821,331 $ - $ 821,331 As of October 9, 2020 As Previously Restatement As Restated Balance Sheet Total assets $ 351,797,538 $ - $ 351,797,538 Liabilities and shareholders’ equity Total current liabilities $ 327,799 $ - $ 327,799 Deferred underwriting commissions 12,250,000 - 12,250,000 Derivative warrant liabilities - 21,616,670 21,616,670 Total liabilities 12,577,799 21,616,670 34,194,469 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption 334,219,730 (21,616,670 ) 312,603,060 Shareholders’ equity Preference shares - $0.0001 par value - - - Class A ordinary shares - $0.0001 par value 158 216 374 Class B ordinary shares - $0.0001 par value 1,006 - 1,006 Additional paid-in-capital 5,038,954 806,726 5,845,680 Accumulated deficit (40,109 ) (806,942 ) (847,051 ) Total shareholders’ equity 5,000,009 - 5,000,009 Total liabilities and shareholders’ equity $ 351,797,538 - $ 351,797,538

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	5 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of basic and diluted net income (loss) per ordinary share	For the Class A ordinary shares subject to possible redemption Numerator: Net gain from investments held in Trust Account $ 7,007 Net income attributable to Class A ordinary shares subject to possible redemption $ 7,007 Denominator: Weighted average shares outstanding of Class A ordinary shares subject to possible redemption, basic and diluted 32,831,343 Basic and diluted net income per share, Class A ordinary shares subject to possible redemption $ 0.00 Non-redeemable ordinary shares Numerator: Net loss $ (6,674,151 ) Less: Net income attributable to Class A ordinary shares subject to possible redemption 7,007 Net loss attributable to non-redeemable ordinary shares $ (6,681,158 ) Denominator: Weighted average shares outstanding of non-redeemable ordinary shares, basic and diluted 11,002,709 Basic and diluted net loss per share, non-redeemable ordinary shares $ (0.61 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	5 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of financial assets are measured at fair value	Fair Value Measured as of December 31, 2020 Level 1 Level 2 Level 3 Total Liabilities: Derivative warrant liabilities Public Warrants (Restated) $ 18,683,920 $ - $ - $ 18,683,920 Derivative warrant liabilities Private Warrants (Restated) $ - $ - $ 9,816,670 $ 9,816,670 Total fair value $ 18,683,920 $ - $ 9,816,670 $ 28,500,590
Schedule of fair value measurements inputs	As of October 09, As of December 31, Exercise price 11.50 11.50 Stock Price 9.60 10.07 Option term (in years) 6.67 6.44 Volatility 19.8 % 21.0 % Risk-free interest rate 0.52 % 0.57 %
Schedule of fair value of derivative warrant liabilities	Level 3 - Derivatrive warrant liabilities at July 29, 2020 (inception) $ - Level 3 - Derivatrive warrant liabilities at September 30, 2020 - Issuance of Public and Private Warrants 23,041,670 Transfer to Level 1 measurement - Public Warrants (18,683,920 ) Change in fair value of derivative warrant liabilities 5,458,920 Level 3 - Derivative warrant liabilities at December 31, 2020 $ 9,816,670

Description of Organization, _2

Description of Organization, Business Operations and Basis of Presentation (Details) - USD ($)	Oct. 09, 2020	Nov. 17, 2020	Dec. 31, 2020
Description of Organization, Business Operations and Basis of Presentation (Details) [Line Items]
Offering costs			$ 375,000,000
Gross proceeds from IPO			$ 375,000,000
Fair market value, percentage			80.00%
Ownership percentage			50.00%
Exercise price (in Dollars per share)			$ 10
Net tangible assets			$ 5,000,001
Aggregate of public share, percentage			15.00%
Percentage of public shares			100.00%
Dissolution expenses			$ 100,000
Price per share (in Dollars per share)			$ 10
Public per share (in Dollars per share)			10
Trust account per share price (in Dollars per share)			$ 10
Balance at bank			$ 821,000
Working capital deficit			1,200,000
Loan amount			$ 300,000
Initial public offering [Member]
Description of Organization, Business Operations and Basis of Presentation (Details) [Line Items]
Initial public offering units (in Shares)	35,000,000
Price per unit (in Dollars per share)	$ 10
Generating gross proceeds	$ 350,000,000
Offering costs	19,800,000
Deferred underwriting commissions	$ 12,300,000
Over-Allotment Units [Member]
Description of Organization, Business Operations and Basis of Presentation (Details) [Line Items]
Initial public offering units (in Shares)		2,500,000
Generating gross proceeds		$ 25,000,000
Underwriting Fees		1,400,000
Deferred underwriting fees		$ 875,000
Private placement warrants [Member]
Description of Organization, Business Operations and Basis of Presentation (Details) [Line Items]
Price per unit (in Dollars per share)			$ 1.50
Initial public offering warrants (in Shares)			6,000,000
Gross proceeds			$ 9,000,000
Exercise price (in Dollars per share)			$ 11.50
Private placement warrants overallotment [Member]
Description of Organization, Business Operations and Basis of Presentation (Details) [Line Items]
Initial public offering units (in Shares)		333,334
Price per unit (in Dollars per share)			$ 10
Generating gross proceeds		$ 500,000
Gross proceeds		$ 500,000
Gross proceeds from IPO			$ 375,000,000
Founder Shares [Member]
Description of Organization, Business Operations and Basis of Presentation (Details) [Line Items]
Sponsor payment			25,000
Loan amount			$ 300,000

Restatement of Previously Iss_3

Restatement of Previously Issued Financial Statements (Details) $ in Millions	Oct. 09, 2020USD ($)
Condensed Financial Information Disclosure [Abstract]
Derivative warrant liabilities	$ 21.6

Restatement of Previously Iss_4

Restatement of Previously Issued Financial Statements (Details) - Schedule of the restatement on each financial statement - USD ($)	5 Months Ended
	Dec. 31, 2020	Oct. 09, 2020
As Previously Reported [Member]
Balance Sheet
Total assets	$ 376,272,470	$ 351,797,538
Total current liabilities	122,735	327,799
Deferred underwriting commissions	13,125,000	12,250,000
Derivative warrant liabilities
Total liabilities	13,247,735	12,577,799
Class A ordinary shares, $0.0001 par value; shares subject to possible redemption	358,024,730	334,219,730
Shareholders’ equity
Preference shares - $0.0001 par value
Additional paid-in-capital	5,351,344	5,038,954
Accumulated deficit	(352,446)	(40,109)
Total shareholders’ equity	5,000,005	5,000,009
Total liabilities and shareholders’ equity	376,272,470	351,797,538
Statement of Operations and Comprehensive Loss
Loss from operations	(360,420)
Change in fair value of derivative warrant liabilities
Net gain from cash equivalents held in Trust Account	7,974
Total other (expense) income	7,974
Net loss	(352,446)
Adjustment to reconcile net loss to net cash used in operating activities	(373,404)
Net cash used in operating activities	(725,850)
Net cash used in investing activities	(375,000,000)
Net cash provided by financing activities	$ 376,547,181
Weighted average shares outstanding of Class A ordinary shares subject to possible redemption, basic and diluted (in Shares)	35,001,205
Basic and diluted net income per share, Class A ordinary shares subject to possible redemption (in Dollars per share)
Weighted average shares outstanding of non-redeemable ordinary shares, basic and diluted (in Shares)	9,819,148
Basic and diluted net loss per share, non-redeemable ordinary shares (in Dollars per share)	$ (0.04)
Net change in cash	$ 821,331
As Previously Reported [Member] | Class A ordinary shares
Shareholders’ equity
Ordinary shares - $0.0001 par value	170	158
As Previously Reported [Member] | Class B ordinary shares
Shareholders’ equity
Ordinary shares - $0.0001 par value	937	1,006
Restatement Adjustment [Member]
Balance Sheet
Total assets
Total current liabilities
Deferred underwriting commissions
Derivative warrant liabilities	28,500,590	21,616,670
Total liabilities	28,500,590	21,616,670
Class A ordinary shares, $0.0001 par value; shares subject to possible redemption	(28,500,590)	(21,616,670)
Shareholders’ equity
Preference shares - $0.0001 par value
Additional paid-in-capital	6,321,420	806,726
Accumulated deficit	(6,321,705)	(806,942)
Total shareholders’ equity
Total liabilities and shareholders’ equity
Statement of Operations and Comprehensive Loss
Loss from operations
Change in fair value of derivative warrant liabilities	(5,458,920)
Financing cost - derivative warrant liabilities	(862,785)
Net gain from cash equivalents held in Trust Account
Total other (expense) income	(6,321,705)
Net loss	(6,321,705)
Adjustment to reconcile net loss to net cash used in operating activities	5,458,920
Net cash used in operating activities
Net cash used in investing activities
Net cash provided by financing activities
Weighted average shares outstanding of Class A ordinary shares subject to possible redemption, basic and diluted (in Shares)	(2,169,862)
Basic and diluted net income per share, Class A ordinary shares subject to possible redemption (in Dollars per share)
Weighted average shares outstanding of non-redeemable ordinary shares, basic and diluted (in Shares)	1,183,561
Basic and diluted net loss per share, non-redeemable ordinary shares (in Dollars per share)	$ (0.57)
Net change in cash
Restatement Adjustment [Member] | Class A ordinary shares
Shareholders’ equity
Ordinary shares - $0.0001 par value	285	216
Restatement Adjustment [Member] | Class B ordinary shares
Shareholders’ equity
Ordinary shares - $0.0001 par value
As Restated [Member]
Balance Sheet
Total assets	376,272,470	351,797,538
Total current liabilities	122,735	327,799
Deferred underwriting commissions	13,125,000	12,250,000
Derivative warrant liabilities	28,500,590	21,616,670
Total liabilities	41,748,325	34,194,469
Class A ordinary shares, $0.0001 par value; shares subject to possible redemption	329,524,140	312,603,060
Shareholders’ equity
Preference shares - $0.0001 par value
Additional paid-in-capital	11,672,764	5,845,680
Accumulated deficit	(6,674,151)	(847,051)
Total shareholders’ equity	5,000,005	5,000,009
Total liabilities and shareholders’ equity	376,272,470	351,797,538
Statement of Operations and Comprehensive Loss
Loss from operations	(360,420)
Change in fair value of derivative warrant liabilities	(5,458,920)
Financing cost - derivative warrant liabilities	(862,785)
Net gain from cash equivalents held in Trust Account	7,974
Total other (expense) income	(6,313,731)
Net loss	(6,674,151)
Adjustment to reconcile net loss to net cash used in operating activities	5,085,516
Net cash used in operating activities	(725,850)
Net cash used in investing activities	(375,000,000)
Net cash provided by financing activities	$ 376,547,181
Weighted average shares outstanding of Class A ordinary shares subject to possible redemption, basic and diluted (in Shares)	32,831,343
Basic and diluted net income per share, Class A ordinary shares subject to possible redemption (in Dollars per share)
Weighted average shares outstanding of non-redeemable ordinary shares, basic and diluted (in Shares)	11,002,709
Basic and diluted net loss per share, non-redeemable ordinary shares (in Dollars per share)	$ (0.61)
Net change in cash	$ 821,331
As Restated [Member] | Class A ordinary shares
Shareholders’ equity
Ordinary shares - $0.0001 par value	455	374
As Restated [Member] | Class B ordinary shares
Shareholders’ equity
Ordinary shares - $0.0001 par value	$ 937	$ 1,006

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details)	5 Months Ended
	Dec. 31, 2020USD ($)shares
Summary of Significant Accounting Policies (Details) [Line Items]
Net proceeds (in Dollars) | $	$ 375,000,000
Federal depository insurance coverage amount (in Dollars) | $	250,000
Financing cost derivative warrant liabilities (in Dollars) | $	$ 862,785
Shares subject to possible redemption	32,952,414
Issuance of private placement warrants	6,333,334
Shares subject to possible redemption	32,952,414
Initial Public Offering [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Financing cost derivative warrant liabilities (in Dollars) | $	$ 900,000
Stockholders equity (in Dollars) | $	$ 20,300,000
Over-Allotment Option [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Warrants to purchase ordinary stock	18,833,334
Class A Ordinary Shares [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Warrent to puchase of common stock	12,500,000
Shares subject to possible redemption	32,952,414

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of basic and diluted net income (loss) per ordinary share	5 Months Ended
	Dec. 31, 2020USD ($)$ / sharesshares
Numerator:
Net gain from investments held in Trust Account	$ 7,007
Net income attributable to Class A ordinary shares subject to possible redemption	$ 7,007
Denominator:
Weighted average shares outstanding of Class A ordinary shares subject to possible redemption, basic and diluted (in Shares) | shares	32,831,343
Basic and diluted net income per share, Class A ordinary shares subject to possible redemption (in Dollars per share) | $ / shares	$ 0
Numerator:
Net loss	$ (6,674,151)
Less: Net income attributable to Class A ordinary shares subject to possible redemption	7,007
Net loss attributable to non-redeemable ordinary shares	$ (6,681,158)
Denominator:
Weighted average shares outstanding of non-redeemable ordinary shares, basic and diluted (in Shares) | shares	11,002,709
Basic and diluted net loss per share, non-redeemable ordinary shares (in Dollars per share) | $ / shares	$ (0.61)

Initial Public Offering (Detail

Initial Public Offering (Details) - USD ($)	Oct. 09, 2020	Nov. 17, 2020	Dec. 31, 2020
Initial Public Offering (Details) [Line Items]
Warrant Description			Each Unit consists of one Class A ordinary share and one-third of one redeemable warrant (“Public Warrant”). Each whole Public Warrant will entitle the holder to purchase one Class A ordinary share at an exercise price of $11.50 per share, subject to adjustment (see Note 8).
Initial public offering [Member]
Initial Public Offering (Details) [Line Items]
Initial public offering units (in Shares)	35,000,000
Price per unit (in Dollars per share)	$ 10
Gross proceeds	$ 350,000,000
Offering costs	19,800,000
Deferred underwriting commissions	12,300,000
Generating gross proceeds	$ 350,000,000
Over-allotment units [Member]
Initial Public Offering (Details) [Line Items]
Initial public offering units (in Shares)		2,500,000
Generating gross proceeds		$ 25,000,000
Underwriting fees		1,400,000
Deferred underwriting fees		$ 875,000
Class A Ordinary Shares [Member]
Initial Public Offering (Details) [Line Items]
Exercise price (in Shares)			11.50

Private Placement (Details)

Private Placement (Details) - USD ($)	1 Months Ended	5 Months Ended
	Nov. 17, 2020	Dec. 31, 2020
Private placement warrant [Member]
Private Placement (Details) [Line Items]
Initial public offering warrants		6,000,000
Gross proceeds		$ 9,000,000
Exercise price		$ 11.50
Private placement warrants overallotment [Member]
Private Placement (Details) [Line Items]
Purchase price		$ 1.50
Gross proceeds	$ 500,000
Initial public offering units	333,334

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	Oct. 09, 2020	Jul. 31, 2020	Dec. 31, 2020	Nov. 17, 2020
Related Party Transactions (Details) [Line Items]
Issued and outstanding shares of public offering, percentage			20.00%
Loan amount		$ 300,000
Repaid amount	$ 300,000
Authorized working capital	$ 1,500,000
Price per warrant (in Dollars per share)	$ 1.50		$ 11.50
Administrative service agreement			$ 10,000
Founder Shares [Member]
Related Party Transactions (Details) [Line Items]
Consideration received		$ 25,000
Common stock subject to forfeiture (in Shares)		1,312,500
Issued and outstanding shares of public offering, percentage		20.00%
Sale of additional units (in Shares)				2,500,000
Business combination, description			The Initial Shareholders agreed not to transfer, assign or sell any of their Founder Shares until the earlier to occur of (A) one year after the completion of the initial Business Combination; and (B) subsequent to the initial Business Combination (x) if the last reported sale price of Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property.
Class B ordinary shares [Member]
Related Party Transactions (Details) [Line Items]
Shares issued (in Shares)		10,062,500
Aggregate additional shares forfeited (in Shares)				687,500

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	1 Months Ended	5 Months Ended
	Nov. 17, 2020	Dec. 31, 2020
Commitments and Contingencies (Details) [Line Items]
Additional fee paid	$ 500,000
Deferred underwriting commissions	$ 875,000
Description of deferred fees		The Company’s legal counsel agreed to defer their fees in excess of $250,000 until the consummation of the Company’s initial Business Combination.
Business combination, term		2 years
Initial Public Offering [Member]
Commitments and Contingencies (Details) [Line Items]
Purchase of additional shares		5,250,000
Over-Allotment [Member]
Commitments and Contingencies (Details) [Line Items]
Purchase of additional shares	2,500,000
Underwriting agreement, description		The underwriters were entitled to an underwriting discount of $0.20 per unit, or $7.00 million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, $0.35 per unit, or $12.25 million in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.

Warrants (Details)

Warrants (Details)	5 Months Ended
	Dec. 31, 2020$ / sharesshares	Oct. 09, 2020$ / shares
Warrants (Details) [Line Items]
Warrants exercise price	$ 11.50	$ 1.50
Warrant expire term	5 years
Business combination, description	In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described under “Redemption of warrants for cash when the price per Class A ordinary share equals or exceeds $18.00” and “Redemption of warrants for Class A ordinary shares when the price per Class A ordinary share equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described under the caption “Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price.
Trading days description	● upon not less than 30 days’ prior written notice of redemption to each warrant holder; and ● if, and only if, the last reported sale price of Class A ordinary shares for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders (the “Reference Value”) equals or exceeds $18.00 per share (as adjusted for share sub-divisions, share dividends, rights issuances, consolidations, reorganizations, recapitalizations and the like).
Trading days	10
Private Placement Warrants [Member]
Warrants (Details) [Line Items]
Warrants exercise price	$ 0.01
Public Warrants and Private Placement Warrants [Member]
Warrants (Details) [Line Items]
Warrants for redemption description	● in whole and not in part; ● at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the “fair market value” of Class A ordinary shares; ● if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted for share splits, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like); and ● if the Reference Value is less than $18.00 per share (as adjusted), the Private Placement Warrants must also concurrently be called for redemption on the same terms as the outstanding Public Warrants, as described above.
Class A ordinary shares
Warrants (Details) [Line Items]
Warrants to purchase shares (in Shares) | shares	12,500,000
Issuance of private placement warrants (in Shares) | shares	6,333,334
Redemption of warrants for cash	$ 18
Class A ordinary shares | Public Warrants and Private Placement Warrants [Member]
Warrants (Details) [Line Items]
Redemption of warrants for cash	$ 10

Shareholder_s Equity (Details)

Shareholder’s Equity (Details) - $ / shares	1 Months Ended	5 Months Ended
	Jul. 31, 2020	Dec. 31, 2020	Nov. 17, 2020
Shareholder’s Equity (Details) [Line Items]
Issued and outstanding, percentage	20.00%
Issued and outstanding shares of public offering, percentage		20.00%
Preferred stock, shares authorized		5,000,000
Preferred stock par value (in Dollars per share)		$ 0.0001
Warrant [Member]
Shareholder’s Equity (Details) [Line Items]
Warrants, description		In the case that additional Class A ordinary shares, or equity-linked securities, are issued or deemed issued in excess of the amounts issued in the Initial Public Offering and related to the closing of the initial Business Combination, the ratio at which the Class B ordinary shares will convert into Class A ordinary shares will be adjusted (unless the holders of a majority of the issued and outstanding Class B ordinary shares agree to waive such anti-dilution adjustment with respect to any such issuance or deemed issuance) so that the number of Class A ordinary shares issuable upon conversion of all Class B ordinary shares will equal, in the aggregate, on an as-converted basis, 20% of the sum of all ordinary shares issued and outstanding upon the completion of the Initial Public Offering plus all Class A ordinary shares and equity-linked securities issued or deemed issued in connection with the initial Business Combination, excluding any shares or equity-linked securities issued, or to be issued, to any seller in the initial Business Combination.
Exercise price 10.00 [Member]
Shareholder’s Equity (Details) [Line Items]
Warrants for redemption, description		On July 31, 2020, the Company issued 10,062,500 Class B ordinary shares, including an aggregate of up to 1,312,500 Class B ordinary shares that are subject to forfeiture, to the Company by the Initial Shareholders for no consideration to the extent that the underwriters’ over-allotment option is not exercised in full or in part, so that the Initial Shareholders will collectively own 20% of the Company’s issued and outstanding ordinary shares after the Initial Public Offering.
Exercise price 18.00 [Member]
Shareholder’s Equity (Details) [Line Items]
Warrants for redemption, description		The Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the initial Business Combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like, and subject to further adjustment as provided herein.
Class A Ordinary Shares [Member]
Shareholder’s Equity (Details) [Line Items]
Common stock, shares authorized		500,000,000
Common stock par value (in Dollars per share)		$ 0.0001
Common stock, shares issued		37,500,000
Ordinary Shares Subject To Possible Redemption		32,952,414
Shares issued under over-allotment			2,500,000
Class B Ordinary Shares [Member]
Shareholder’s Equity (Details) [Line Items]
Common stock, shares authorized		50,000,000
Common stock par value (in Dollars per share)		$ 0.0001
Common stock, shares issued	10,062,500
Common stock subject to possible forfeiture	1,312,500
Aggregate additional shares forfeited			687,500

Fair Value Measurements (Detail

Fair Value Measurements (Details) $ in Millions	5 Months Ended
	Dec. 31, 2020USD ($)
Fair Value Disclosures [Abstract]
Unrealized loss from fair value	$ 5.5

Fair Value Measurements (Deta_2

Fair Value Measurements (Details) - Schedule of financial assets are measured at fair value	Dec. 31, 2020USD ($)
Liabilities:
Derivative warrant liabilities (Restated)	$ 18,683,920
Derivative warrant liabilities Private Warrants (Restated)	9,816,670
Total fair value	28,500,590
Level 1 [Member]
Liabilities:
Derivative warrant liabilities (Restated)	18,683,920
Derivative warrant liabilities Private Warrants (Restated)
Total fair value	18,683,920
Level 2 [Member]
Liabilities:
Derivative warrant liabilities (Restated)
Derivative warrant liabilities Private Warrants (Restated)
Total fair value
Level 3 [Member]
Liabilities:
Derivative warrant liabilities (Restated)
Derivative warrant liabilities Private Warrants (Restated)	9,816,670
Total fair value	$ 9,816,670

Fair Value Measurements (Deta_3

Fair Value Measurements (Details) - Schedule of fair value measurements inputs - Fair Value, Inputs, Level 3 [Member] - $ / shares	2 Months Ended	5 Months Ended
	Oct. 09, 2020	Dec. 31, 2020
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Exercise price	$ 11.50	$ 11.50
Stock Price	$ 9.60	$ 10.07
Option term (in years)	6 years 244 days	6 years 160 days
Volatility	19.80%	21.00%
Risk-free interest rate	0.52%	0.57%

Fair Value Measurements (Deta_4

Fair Value Measurements (Details) - Schedule of fair value of derivative warrant liabilities - Level 3 [Member]	5 Months Ended
	Dec. 31, 2020USD ($)
Fair Value Measurements (Details) - Schedule of fair value of derivative warrant liabilities [Line Items]
Level 3 - Derivatrive warrant liabilities
Level 3 - Derivatrive warrant liabilities at September 30, 2020
Issuance of Public and Private Warrants	23,041,670
Transfer to Level 1 measurement - Public Warrants	(18,683,920)
Change in fair value of derivative warrant liabilities	5,458,920
Level 3 - Derivatrive warrant liabilities	$ 9,816,670

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($)	1 Months Ended
	Feb. 21, 2021	Mar. 29, 2021
Subsequent Events (Details) [Line Items]
Merger agreement. description	(ii) as a result of the Merger, among other things, all outstanding shares of common stock of Xos (after giving effect to the Company Recapitalization (as defined in the Merger Agreement)) will be cancelled in exchange for the right to receive, in the aggregate, a number of shares of the Company’s Common Stock (as defined below) equal to the quotient obtained by dividing (x) $1,276,261,160.00 by (y) $10.00; and
Promissory Note [Member]
Subsequent Events (Details) [Line Items]
Aggregate principal amount		$ 1,000,000
Promissory Note outstanding		$ 0
PIPE Investors [Member]
Subsequent Events (Details) [Line Items]
Shares subscribed (in Shares)	22,000,000
Aggregate purchase price for shares	$ 220,000,000
Additional shares to be sold (in Shares)	2,000,000